CRYO CELL INTERNATIONAL INC (CCEL): Nasdaq/NYSE listing notice — NYSE American accepts Cryo-Cell compliance plan; trading continues through Sep 2027

CRYO CELL INTERNATIONAL INC

Received notice of non-compliance on Mar 12, 2026 for stockholders' deficit and net losses in two of three fiscal years ending Nov 30, 2025.
Compliance plan accepted May 6, 2026; plan period extends to September 9, 2027 to regain listing standards.
Common stock remains listed and traded on NYSE American during plan period, subject to periodic review.
Failure to regain compliance or make progress by deadline could result in delisting proceedings.
Company reported stockholders' deficit as of Nov 30, 2025 and net losses in FY2023, FY2024, FY2025.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.75

CRYO CELL INTERNATIONAL INC received a nyse_american extension granted notice regarding other.

Exchange: nyse american
Notice: extension granted

Exact text from the filing

May 6, 2026, Cryo-Cell International, Inc. (the "Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the N

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CRYO CELL INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001193125-26-214569

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.